ASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation

Stock News

06/08

ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana. The presentations highlighted the company's differentiated pipeline in obesity treatment, featuring a small molecule candidate, a peptide drug, and an oral peptide delivery enhancement technology.

The data showcased at the event garnered significant attention from leading experts in attendance, further underscoring ASCLETIS-B's innovative capabilities in the field of metabolic disease therapies.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1102346844"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102346844\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102346844?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 08:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102346844","market":"us","top_or_hot":-1,"title":"ASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation","media":"Stock News","content":"<p>ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana. The presentations highlighted the company's differentiated pipeline in obesity treatment, featuring a small molecule candidate, a peptide drug, and an oral peptide delivery enhancement technology.<br><br>The data showcased at the event garnered significant attention from leading experts in attendance, further underscoring ASCLETIS-B's innovative capabilities in the field of metabolic disease therapies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-08 08:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana. The presentations highlighted the company's differentiated pipeline in obesity treatment, featuring a small molecule candidate, a peptide drug, and an oral peptide delivery enhancement technology.<br><br>The data showcased at the event garnered significant attention from leading experts in attendance, further underscoring ASCLETIS-B's innovative capabilities in the field of metabolic disease therapies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"","article_id":"1102346844","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102346844","pubTimestamp":1780877777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B","BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","01672":"歌礼制药-B"},"translate_title":"歌礼-B在ADA 2026上展示了令人信服的肥胖产品组合临床和临床前数据，加强了产品线的差异化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1,"01477":1},"content_text":"ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana. The presentations highlighted the company's differentiated pipeline in obesity treatment, featuring a small molecule candidate, a peptide drug, and an oral peptide delivery enhancement technology.The data showcased at the event garnered significant attention from leading experts in attendance, further underscoring ASCLETIS-B's innovative capabilities in the field of metabolic disease therapies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}